Clinical and Device Functional Assessment of Real World ICD Patients

Overview

The primary requirement of the implantable cardioverter defibrillator (ICD) is to preserve life by terminating life-threatening arrhythmias (VT/VF). The treatment options vary in terms of techniques and medical devices, based on the patient's condition. It is extremely important in the clinical practice to identify which patients' subgroup benefits the most from the ICD therapy, which comorbidity has a major impact on the patients' prognosis, or which pre-intra-post procedural behaviors provoke less complications, and affect the patient's outcome (including prolonged or unwanted hospitalizations).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 26, 2019

Detailed Description

For these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing ICD/CRT-D device implantation (first implant, replacement or upgrade). The safety and performance of the ICDs can be evaluated through the collection of multiple parameters such as, but not limited to: – Clinical parameters, like patient demographics and history, procedural and hospital discharge data, as well as the short and long term serious adverse events (death and hospitalization) – Device parameters, such as delivered shocks, ATP, or other device therapies Worldwide selected centers will be invited to participate in this prospective study and include their "real-world" patients treated with Sorin Group commercially available ICDs and CRT-Ds devices.

Interventions

  • Device: ICD
    • ICD single, dual or triple chamber, upgrade, replacement or primo implant

Clinical Trial Outcome Measures

Primary Measures

  • Evaluate clinical and device functional information from “real world” ICD patient population following standard of care at participating centers w/in the different participating countries (Incidence of all death, device,cardiac related hospitalization)
    • Time Frame: 2 years
    • Incidence of all death, device and/or cardiac related hospitalization at 24 months post implant

Secondary Measures

  • Serious procedural complications or other SAE at implantation or hospital discharge. The data analyzed are those collected from the day of implantation to the day of hospital discharge, with an expected average of 1 week.
    • Time Frame: at implantation or hospital discharge
    • as reported by the sites on the AE eCRF
  • The incidence of all death, device and/or cardiac related hospitalization at 12 months post implant (evaluated with a survival curve)
    • Time Frame: at 12 months
    • as reported by the sites with AE
  • The predictors of mortality and cardiac related hospitalization at 12 and 24 months
    • Time Frame: at 12 and 24 months
    • as reported by the sites with AE and medical history information
  • The predictors of appropriate or inappropriate therapies (ATP and shocks) at 12 and 24 months, as verified by a dedicated committee
    • Time Frame: at 12 and 24 months
    • based on therapies delivered recorder on device file, and verified by a dedicated committee
  • The evolution of the indication for implant according to guideline (based on the patient’s medical history and reason for implant as reported by the investigators)
    • Time Frame: at implant
    • based on the patient’s medical history and reason for implant as reported by the investigators

Participating in This Clinical Trial

Inclusion Criteria

  • Patient Implanted (first implant, replacement, upgrade) with a Sorin Group ICD/CRT-D device, according to current available guidelines and IFU – Signed and dated informed consent (in accordance to local regulation) Exclusion Criteria:

  • Already included in another clinical study that could confound the results of this study – Not available for routine follow-up visits – Minor age – Drug addiction or abuse

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • MicroPort CRM
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Javier Moreno, Dr, Principal Investigator, Hospital Ramón y Cajal Ctra. de Colmenar Viejo km 9.100, 28034 Madrid, Spain

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.